Figure 1
From: Aberrant Methylation of MEG3 Functions as a Potential Plasma-Based Biomarker for Cervical Cancer
Analysis of methylation status of MEG3 promoter in plasmas and tissues using MSP. (a) MSP products illustrated that methylated pattern was largely detected in plasmas of cervical cancer patients (C1-C5 as examples) while unmethylated pattern was found in most of healthy participants’ plasmas (N1–N5 as examples). (b) The percentage of M, MU and U in plasmas of cervical cancer patients and healthy participants respectively. (c) The percentage of M, MU and U in cervical cancer tissues and adjacent normal tissues respectively. (d) The methylation level of MEG3 promoter in cervical cancer patients’ plasmas and cervical cancer tissues was significantly higher compared with their controls respectively. (e) ROC curve analysis for the diagnosis of cervical cancer by MEG3 methylation in plasma. MSP, methylation-specific polymerase chain reaction; M, methylated pattern; MU, partially methylated pattern; U, unmethylated pattern. **P < 0.01.
